Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

DPYD*2A mutation: the most common mutation associated with DPD deficiency.

Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB.

Cancer Chemother Pharmacol. 2007 Sep;60(4):503-7.

PMID:
17165084
2.
3.

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.

Ezzeldin HH, Lee AM, Mattison LK, Diasio RB.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8699-705.

5.

Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.

Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C.

Clin Biochem. 2010 Feb;43(3):331-4. doi: 10.1016/j.clinbiochem.2009.09.024.

PMID:
19822137
7.

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.

Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF.

Cancer Chemother Pharmacol. 2004 May;53(5):445-51.

PMID:
15132136
8.

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

van Kuilenburg AB.

Eur J Cancer. 2004 May;40(7):939-50. Review.

PMID:
15093568
9.
10.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.

Magy Onkol. 2007;51(2):113-25. Hungarian.

11.

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.

He YF, Wei W, Zhang X, Li YH, Li S, Wang FH, Lin XB, Li ZM, Zhang DS, Huang HQ, Hu B, Jiang WQ.

J Clin Pharm Ther. 2008 Jun;33(3):307-14. doi: 10.1111/j.1365-2710.2008.00898.x.

PMID:
18452418
12.

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.

Lee A, Ezzeldin H, Fourie J, Diasio R.

Clin Adv Hematol Oncol. 2004 Aug;2(8):527-32. Review.

PMID:
16163233
13.

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

Amstutz U, Farese S, Aebi S, Largiadèr CR.

J Exp Clin Cancer Res. 2008 Oct 20;27:54. doi: 10.1186/1756-9966-27-54.

14.

Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.

Bosch TM, Bakker R, Schellens JH, Cats A, Smits PH, Beijnen JH.

Mol Diagn Ther. 2007;11(2):105-8.

PMID:
17397246
15.

Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

Paré L, Paez D, Salazar J, Del Rio E, Tizzano E, Marcuello E, Baiget M.

Br J Clin Pharmacol. 2010 Aug;70(2):268-72. doi: 10.1111/j.1365-2125.2010.03683.x.

16.
17.

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.

Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E.

Clin Cancer Res. 2005 Aug 15;11(16):5886-92.

18.

High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.

Gross E, Seck K, Neubauer S, Mayr J, Hellebrand H, Ratanaphan A, Lutz V, Stockinger H, Kiechle M.

Int J Oncol. 2003 Feb;22(2):325-32.

PMID:
12527930
19.

Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH.

Clin Cancer Res. 2001 May;7(5):1149-53.

Supplemental Content

Support Center